title: Melanoma in 2015: Immune-checkpoint blockade - durable cancer control.
authors.affiliation: Melanoma Disease Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215-05450, USA.
authors.forename: Elizabeth I
authors.initials: EI
authors.lastname: Buchbinder
authors.affiliation: Melanoma Disease Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215-05450, USA.
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D060908:CTLA-4 Antigen / Q000276:immunology; D017326:Clinical Trials, Phase III as Topic; D018816:Genes, cdc / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D000074324:Ipilimumab; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D009362:Neoplasm Metastasis; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D000074324:Ipilimumab; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab